Executive interview – InMed: Leading the way in the therapeutic development of cannabinol (CBN)

Executive interview – InMed: Leading the way in the therapeutic development of cannabinol (CBN)

InMed Pharmaceuticals — 14 videos in collection

In this video, InMed’s CEO Eric A Adams speaks about the company’s therapeutic development of cannabinol (CBN), a rare cannabinoid showing potential to treat serious diseases with high unmet needs. InMed is the first company to advance CBN into clinical trials for therapeutic development. Mr Adams also provides an update on the company’s programs in epidermolysis bullosa (EB) and glaucoma and its biosynthesis platform.

InMed is a biopharmaceutical company focused on manufacturing and developing cannabinoids. Its main pipeline product is INM-755 for epidermolysis bullosa, a serious, debilitating orphan indication.


You may also be interested in these:

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.